BRIDGEBIO PHARMA ($BBIO) posted quarterly earnings results on Wednesday, October 29th. The company reported earnings of -$0.95 per share, missing estimates of -$0.89 by $0.06. The company also reported revenue of $120,700,000, beating estimates of $108,514,107 by $12,185,893.
You can see Quiver Quantitative's $BBIO stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BRIDGEBIO PHARMA Insider Trading Activity
BRIDGEBIO PHARMA insiders have traded $BBIO stock on the open market 54 times in the past 6 months. Of those trades, 0 have been purchases and 54 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by insiders over the last 6 months:
- GENETIC DISORDER L.P. KKR sold 6,000,000 shares for an estimated $205,200,000
- GLOBAL INVESTORS LP VIKING sold 3,500,000 shares for an estimated $154,000,000
- NEIL KUMAR (Chief Executive Officer) has made 0 purchases and 35 sales selling 447,312 shares for an estimated $20,290,345.
- CHARLES J HOMCY has made 0 purchases and 3 sales selling 300,000 shares for an estimated $13,912,442.
- FRANK MCCORMICK has made 0 purchases and 2 sales selling 174,000 shares for an estimated $8,356,344.
- ANDREW LO sold 100,000 shares for an estimated $3,849,900
- THOMAS TRIMARCHI (President and CFO) has made 0 purchases and 3 sales selling 59,590 shares for an estimated $2,961,803.
- ANDREA ELLIS sold 17,167 shares for an estimated $841,183
- HANNAH VALANTINE has made 0 purchases and 5 sales selling 8,999 shares for an estimated $379,007.
- MARICEL APULI (Chief Accounting Officer) has made 0 purchases and 2 sales selling 2,026 shares for an estimated $84,949.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BRIDGEBIO PHARMA Hedge Fund Activity
We have seen 217 institutional investors add shares of BRIDGEBIO PHARMA stock to their portfolio, and 142 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- KOHLBERG KRAVIS ROBERTS & CO. L.P. removed 6,000,000 shares (-31.2%) from their portfolio in Q2 2025, for an estimated $259,080,000
- VIKING GLOBAL INVESTORS LP removed 3,500,000 shares (-15.9%) from their portfolio in Q2 2025, for an estimated $151,130,000
- CITADEL ADVISORS LLC removed 2,598,708 shares (-88.7%) from their portfolio in Q2 2025, for an estimated $112,212,211
- FARALLON CAPITAL MANAGEMENT LLC added 2,169,000 shares (+37.8%) to their portfolio in Q2 2025, for an estimated $93,657,420
- JANUS HENDERSON GROUP PLC added 2,105,133 shares (+29.4%) to their portfolio in Q2 2025, for an estimated $90,899,642
- MACQUARIE GROUP LTD added 2,003,713 shares (+2189.3%) to their portfolio in Q2 2025, for an estimated $86,520,327
- D. E. SHAW & CO., INC. added 1,998,104 shares (+2403.0%) to their portfolio in Q2 2025, for an estimated $86,278,130
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BRIDGEBIO PHARMA Congressional Stock Trading
Members of Congress have traded $BBIO stock 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 2 purchases worth up to $30,000 on 09/22, 08/08 and 0 sales.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
BRIDGEBIO PHARMA Analyst Ratings
Wall Street analysts have issued reports on $BBIO in the last several months. We have seen 11 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 10/29/2025
- Raymond James issued a "Outperform" rating on 10/21/2025
- UBS issued a "Buy" rating on 09/12/2025
- JP Morgan issued a "Overweight" rating on 09/03/2025
- Cantor Fitzgerald issued a "Overweight" rating on 07/29/2025
- Jefferies issued a "Buy" rating on 07/14/2025
- Citigroup issued a "Buy" rating on 07/11/2025
To track analyst ratings and price targets for BRIDGEBIO PHARMA, check out Quiver Quantitative's $BBIO forecast page.
BRIDGEBIO PHARMA Price Targets
Multiple analysts have issued price targets for $BBIO recently. We have seen 14 analysts offer price targets for $BBIO in the last 6 months, with a median target of $67.5.
Here are some recent targets:
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $90.0 on 10/29/2025
- Martin Auster from Raymond James set a target price of $59.0 on 10/21/2025
- Eliana Merle from UBS set a target price of $82.0 on 09/12/2025
- Anupam Rama from JP Morgan set a target price of $70.0 on 09/03/2025
- Leland Gershell from Oppenheimer set a target price of $61.0 on 08/06/2025
- Greg Harrison from Scotiabank set a target price of $57.0 on 08/06/2025
- Josh Schimmer from Cantor Fitzgerald set a target price of $95.0 on 07/29/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
